- #182: Combination Therapy with Antidepressants and Vitamin B Complex Compared to Antidepressant Monotherapy
- #181b: Overview of National Health Economic Evaluation Guidelines: International Best Practices and Implications for Austria
- #179: Guidance for Searching and Finding Public Contributions to Pharmaceutical R&D
- #178: Music therapy: Clinical and socioeconomic outcomes and long-term measures in substance use disorder
- #177: Transition from Child and Adolescent to Adult Mental Health Services: Analysis and Comparison of International Models
- #176c: Genetic Testing in Austria. Part C: Detection of PIK3CA/AKT1/PTEN/ESR1 genetic alterations in HR+/HER2– breast cancer
- #176b: Genetic Testing in Austria. Part B: Carrier Screening for Selected Genetic Conditions
- #176a: Genetic Testing in Austria. Part A: Application Fields and Prioritisation Criteria
- #175: Structured Medication Review for Polypharmacy
- #174: Health Economic Reference Cases and Costing Approaches
- #173: Social Prescribing in Primary Care – Development of an Austrian programme theory based on realist evidence
- #172: Telecardiology for heart failure patients: Benefit assessment and evaluation concept for telemedicine-supported care programmes in Austria
- #171b: AI-supported Chest X-Ray Analysis for Lung Cancer Detection
- #171a: Artificial Intelligence for Hospital Documentation Support
- #170c: Further Development of the Programme on Preventive Health Check-Ups in Austria: Screening for Chronic Kidney Disease – a rapid review on benefits, harms and target populations
- #170b: Further Development of the Programme on Preventive Medical Check-Ups in Austria. Risk Scores for Cardiovascular Disease: A Systematic Review
- #170a: Further Development of the Programme on Preventive Health Check-Ups in Austria: Brief interventions for lifestyle counselling Umbrella review and qualitative survey
- #169: Systematic Review of the Long-Term Effectiveness and Safety of Enzyme Replacement Therapy in Mucopolysaccharidoses Disorders and Pompe Disease
- #168: Nudges to Optimise Prescriber Behaviour of Physicians
- #167: Digital health technologies for self-identification of the risk of perinatal mental illness
- #166: CAR-T cell therapy: Updated effectiveness and safety results from real-world evidence: A systematic review
- #165: Trauma Care: Teaching Recovery Technique (TRT) to children and adolescent refugees. Systematic Review and Evaluation of Austrian TRT-Programme at AFYA
- DSD 006: Dorocubicel + unexpanded CD34– cells (Zemcelpro®) for the treatment of haematological malignancies in adults
- DSD 005: Obecabtagene autoleucel (AUCATZYL®) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
- DSD 004: Lifileucel (AMTAGVI®) for previously treated unresectable or metastatic melanoma
- DSD 003: Teprotumumab (TEPEZZA®) for moderate-to-severe thyroid eye disease
- DSD 146: One-stage matrix-assisted cartilage repair with and without bone marrow aspirate concentrate in the knee
- DSD 145: Thermal ablation for early-stage breast cancer: cryoablation, microwave, radiofrequency, high-intensity focused ultrasound, and laser ablation
- DSD 144: Drug-coated balloon catheter for the treatment of urethral stricturesDSD 143: Islet cell transplantation for chronic pancreatitis, type 1 diabetes, with and without kidney transplantation
- Update / DSD 97/3. Update 2025: Leadless cardiac pacemakers
- Update / DSD 129/1. Update 2025: Temporary nitinol implantation for the treatment of benign prostatic hyperplasia
HTA-Information Service Review No.019
Enfortumab Vedotin in combination with Pembrolizumab in Urothelial CancerHTA-Information Service Review No. 018
Telerehabilitation for Movement Support in People with Chronic Back Pain – Rapid Review of EffectivenessHTA-Information Service Review No. 017
Serum eye drops for patients with severe ocular surface diseasHTA-Information Service Review No. 016
Reimbursement models and pricing of digital health technologies and telemonitoring applications
- #241: Tislelizumab (Tevimbra®) with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer
- #233: Tislelizumab (Tevimbra®) in combination with gemcitabine and cisplatin for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma
- #225: Tislelizumab (Tevimbra®) with etoposide and platinum chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer
- #212:Lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
- #210: Datopotamab deruxtecan (Datroway®) for the treatment of unresectable or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer
- #208: Blinatumomab (Blincyto®) monotherapy as part of consolidation therapy for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL)
- #202: Pembrolizumab (Keytruda®) for the treatment of malignant pleural mesothelioma
- #199: Tislelizumab (Tevimbra®) with chemotherapy for the first-line treatment of HER-2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma
- #198 : Tislelizumab (Tevimbra®) with platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma
- #196: Catumaxomab (Korjuny®) for the treatment of malignant ascites